Biohaven Ltd. filed its quarterly report on Form 10-Q with the SEC on October 29, 2026, covering the three and nine months ended September 30, 2026, for NYSE:BHVN.

Key Highlights

  • Net loss of $129.3 million for the three months ended September 30, 2026, compared with $173.4 million in the same period of 2025, according to the filing.
  • Net loss per share was $0.86 basic and diluted for Q3 2026, versus $1.64 in Q3 2025, the company reported.
  • Total assets fell to $263.7 million as of September 30, 2026, down from $451.4 million as of December 31, 2025, per the balance sheet.
  • Cash and cash equivalents were $95.8 million at September 30, 2026, compared with $230.0 million at December 31, 2025.
  • Accumulated deficit reached $2.48 billion as of September 30, 2026, versus $2.08 billion at year-end 2025.
  • 151,055,160 common shares were issued and outstanding as of September 30, 2026, up from 132,775,113 at December 31, 2025.
  • Net cash used in operating activities for the nine months ended September 30, 2026 was $341.9 million, compared with $478.8 million in the prior-year period.

Biohaven Reports Reduced Operating Losses and Declining Cash Position in Q3 2026

According to the filing, Biohaven Ltd. reported total operating expenses of $126.4 million for the three months ended September 30, 2026, consisting of $101.9 million in research and development costs and $24.6 million in general and administrative expenses. This compares with total operating expenses of $169.4 million for the same quarter in 2025, a reduction the company attributed to lower spending in both categories. For the nine months ended September 30, 2026, total operating expenses were $381.7 million, down from $602.6 million in the comparable prior-year period.

The condensed consolidated balance sheet disclosed that Biohaven held $65.4 million in marketable securities as of September 30, 2026, reduced from $89.2 million at December 31, 2025. Notes payable stood at $264.3 million, up from $238.9 million at year-end 2025, reflecting a change in fair value of $22.5 million recorded during the nine-month period, as stated in the cash flow adjustments. Total shareholders' deficit was reported at $98.2 million as of September 30, 2026, compared with positive shareholders' equity of $52.1 million at December 31, 2025.

The company disclosed that it raised $178.9 million through the issuance of common shares during the nine months ended September 30, 2026, with an additional $4.1 million from share issuances under its 2022 Equity Incentive Plan. The filing identified Biohaven as a large accelerated filer incorporated in the British Virgin Islands, with principal offices in New Haven, Connecticut. The company described its focus as "the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, obesity, neuroscience, and oncology," and noted programs involving Kv7 ion channel modulation, MoDE and TRAP protein degradation platforms, and a myostatin-activin pathway agent.

What Was Disclosed

Biohaven's Form 10-Q for Q3 2026 disclosed a net loss of $129.3 million for the quarter and $397.1 million for the nine-month period, a declining cash position, growth in shares outstanding, and a shift to shareholders' deficit on the balance sheet.